Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 637.65 INR
Change Today 0.00 / 0.00%
Volume 0.0
CIPLA On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:06 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Open
664.45
Previous Close
663.95
Day High
664.45
Day Low
635.00
52 Week High
03/10/15 - 752.85
52 Week Low
05/30/14 - 367.50
Market Cap
512.0B
Average Volume 10 Days
2.2M
EPS TTM
17.29
Shares Outstanding
803.0M
EX-Date
08/6/14
P/E TM
36.9x
Dividend
2.00
Dividend Yield
0.31%
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India and internationally. The company offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health, as well as steroids and hormones. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices comprising metered dose inhalers with dose indicators, dry powder inhalers, nasal sprays, nebulisers, non-electrostatic spacers, and infant and baby masks. It exports raw materials, intermediates, prescription drugs, OTC drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Managing Director, Global Chief Executive Off...
Total Annual Compensation: 137.5M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

cipla ltd (CIPLA) Key Developments

Cipla Plans to Invest $15 Million in the New Joint Venture

Cipla earlier in February formed a joint venture agreement with two of its existing business partners in MoroccoSociete Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and The Pharmaceutical Institute (PHI). The company has announced plans to invest $15 million in this new JV, in a move to establish a front-end presence in Morocco's pharmaceutical market.

Cipla Launches 'Hepcvir' Drug in India

Cipla Ltd. announced that it has launched the generic drug Sofosbuvir in India under the brand name 'Hepcvir'. The generic drug Sofosbuvir is the first-in-class NS5B polymerase inhibitor used in the treatment of hepatitis C. The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries.

Cipla Ltd Enters in to Joint Venture Agreement with Biopharm SPA

Cipla Ltd. announced that a binding term sheet has been entered into with the Biopharm SPA, for establishing a joint venture company in Algeria. The JV company will manufacture and market respiratory products facilitating Cipla's front-end presence in Algeria. As per the term sheet, Cipla (EU) Limited, will hold a 40% stake in the JV company while the remainder will be held by a Biopharm-led Algerian consortium. The JV company is expected to make an investment of up to USD 15 million in the construction of a manufacturing facility. Cipla (EU) Limited's initial investment in cash in the JV company is expected to be USD 6 million. The transaction is subject to execution of definitive agreement and applicable approvals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 637.65 INR 0.00

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,289 INR 0.00
Cadila Healthcare Ltd 1,768 INR +7.00
Dr Reddy's Laboratories Ltd 3,484 INR 0.00
Piramal Enterprises Ltd 949.95 INR 0.00
Torrent Pharmaceuticals Ltd 1,218 INR 0.00
View Industry Companies
 

Industry Analysis

CIPLA

Industry Average

Valuation CIPLA Industry Range
Price/Earnings 43.4x
Price/Sales 4.8x
Price/Book 4.8x
Price/Cash Flow 30.9x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit www.cipla.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.